Nalapres (Lisinopril Dihydrate, Hydrochlorothiazide)

Lisinopril Dihydrate, the active ingredient in Nalapres, is an ACE inhibitor presented as an oral tablet for systemic administration. It is formulated together with Hydrochlorothiazide, a thiazide diuretic, to create a fixed‑dose combination that lowers blood pressure in adult patients with hypertension. The product conforms to European Union quality standards.

GNH USA supplies Nalapres as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to EU‑origin antihypertensive medicines and supporting regulatory compliance for each market.

Nalapres is indicated for hypertension, acting on the renin‑angiotensin system and renal sodium handling to achieve blood‑pressure control. - Hypertension: lowers systolic and diastolic blood pressure in adults. - Resistant hypertension: adds diuretic effect when an ACE inhibitor alone is insufficient. - Hypertension with fluid retention: combines vasodilation and natriuresis to improve overall control.

Nalapres may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Increased urination: due to diuretic effect. - Electrolyte disturbances: mild hypokalemia or hyponatremia.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Acute renal impairment: sudden decrease in kidney function. - Hyperkalemia: elevated potassium levels, potentially dangerous.

Before prescribing Nalapres, clinicians should consider several safety measures. - Monitor blood pressure: ensure adequate control without excessive drop. - Assess renal function: check serum creatinine and eGFR regularly. - Check electrolytes: watch for potassium and sodium abnormalities. - Avoid use in pregnancy: potential fetal harm; contraindicated. - Caution with NSAIDs or lithium: may increase risk of renal dysfunction or toxicity. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nalapres can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium therapy: thiazide component can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect kidney function. - Other antihypertensives (beta‑blockers, calcium channel blockers): may increase risk of hypotension. - Antidiabetic agents: ACE inhibition can enhance hypoglycemic response.